A FIRST-IN- HUMAN PHASE 1 STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARM ACO KIN ETICS IN HEALTHY SUBJECTS

Authors
Category Primary study
ConferenceClinical Pharmacology and Therapeutics
Year 2023
This article has no abstract
Epistemonikos ID: 62e4402c35ead538d1181cb40c9fa855ad2bab27
First added on: Apr 30, 2026